108985
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
慢性炎症综合特征可预测早期结直肠癌患者对奥沙利铂和 5 - 氟尿嘧啶的治疗获益
Authors Peng Y, Shang R, Wang ZJ, Ye QY, Tang XY, Cheng XX, Ying HQ
Received 28 July 2025
Accepted for publication 30 September 2025
Published 23 October 2025 Volume 2025:19 Pages 9501—9514
DOI https://doi.org/10.2147/DDDT.S556619
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Anastasios Lymperopoulos
Yue Peng,1,2 Rong Shang,1,2 Zhi-Jie Wang,1,2 Qiu-Ying Ye,3,4 Xiao-Yan Tang,1,2 Xue-Xin Cheng,1,2 Hou-Qun Ying1,4,5
1Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 2School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 3Department of Medical Technology, Jiangxi Medical College, Shangrao, Jiangxi, People’s Republic of China; 4Department of Laboratory Medicine, Central Hospital of Shangrao City, Shangrao, Jiangxi, People’s Republic of China; 5Shangrao Medical Center of The Second Affiliated Hospital of Nanchang University, Shangrao, Jiangxi, People’s Republic of China
Correspondence: Hou-Qun Ying, Department of Clinical Laboratory, Immunity and Inflammation Key Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, No. 1 of Minde Road, Nanchang, 330006, People’s Republic of China, Tel/Fax +86 0791-86297662, Email yinghouqun2013@163.com
Background: Precision delivery of adjuvant chemotherapy (ACT) improves healthcare efficiency and postoperative quality of life in stage II–III colorectal cancer (CRC). However, there remains an unmet need for identifying biomarkers that can predict therapeutic responses to 5-fluorouracil (5-FU) and oxaliplatin.
Methods: We analyzed three independent cohorts (1676 stage II–III surgical cases) to evaluate the prognostic role of 12 inflammatory indices. A novel Chronic Inflammatory Comprehensive Signature (CICS) was developed using multivariable Cox regression. Three-year recurrence-free survival (RFS) and overall survival (OS) were compared between CICS-stratified subgroups (CICS-L vs CICS-H) receiving 5-FU- or oxaliplatin-based ACT.
Results: Two novel inflammatory ratios (FPSIIR, FPSIRIR) and six composite scores (FPSIIS, FPSIRIS, FPSIRS, FASIIS, FASIRS, FASIRIS) independently predicted prognosis across all three cohorts (all plog-rank< 0.05). The CICS demonstrated an AUC of 0.690 for outcome prediction, increasing to 0.724 when combined with CEA-CA19-9. CICS-H patients exhibited reduced chemosensitivity to both agents, with therapeutic benefits primarily confined to the CICS-L subgroup. Comparable favorable RFS was observed in stage II CICS-L patients undergoing 5-FU monotherapy or oxaliplatin-based ACT versus non-ACT treatments (97.73% vs 91.02% vs 91.46%, plog-rank=0.33). Superior survival outcomes and a lower recurrence rate were observed in stage II CICS-H patients receiving 5-FU compared to those receiving oxaliplatin-based ACT. Consistent oxaliplatin benefits were observed in CICS-H and CICS-L patients compared to 5-FU-treated cases in the stage III subgroup. Optimal ACT regimens for patients with CICS-L and CICS-H differ in different stages. The CICS strategy can help patients select a more optimal ACT regimen (RR=0.47, 95% CI=0.35– 0.62, p< 0.01) and enhance therapeutic efficacy (HR=0.70, 95% CI=0.53– 0.92 for RFS; HR=0.70, 95% CI=0.47– 0.97 for OS in stage III CRC).
Conclusion: CICS-quantified cancer-derived inflammation inversely correlates with the therapeutic responsiveness to 5-FU/oxaliplatin. A CICS-guided strategy maximizes survival outcomes while precision-deescalating chemotherapy use without compromising outcomes, establishing a biomarker-driven paradigm for personalized postoperative management of CRC.
Keywords: chronic inflammatory comprehensive signature, CEA-CA19-9-CICS score, oxaliplatin, 5-fluorouracil, colorectal cancer
1Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 2School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 3Department of Medical Technology, Jiangxi Medical College, Shangrao, Jiangxi, People’s Republic of China; 4Department of Laboratory Medicine, Central Hospital of Shangrao City, Shangrao, Jiangxi, People’s Republic of China; 5Shangrao Medical Center of The Second Affiliated Hospital of Nanchang University, Shangrao, Jiangxi, People’s Republic of China
Correspondence: Hou-Qun Ying, Department of Clinical Laboratory, Immunity and Inflammation Key Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, No. 1 of Minde Road, Nanchang, 330006, People’s Republic of China, Tel/Fax +86 0791-86297662, Email yinghouqun2013@163.com
Background: Precision delivery of adjuvant chemotherapy (ACT) improves healthcare efficiency and postoperative quality of life in stage II–III colorectal cancer (CRC). However, there remains an unmet need for identifying biomarkers that can predict therapeutic responses to 5-fluorouracil (5-FU) and oxaliplatin.
Methods: We analyzed three independent cohorts (1676 stage II–III surgical cases) to evaluate the prognostic role of 12 inflammatory indices. A novel Chronic Inflammatory Comprehensive Signature (CICS) was developed using multivariable Cox regression. Three-year recurrence-free survival (RFS) and overall survival (OS) were compared between CICS-stratified subgroups (CICS-L vs CICS-H) receiving 5-FU- or oxaliplatin-based ACT.
Results: Two novel inflammatory ratios (FPSIIR, FPSIRIR) and six composite scores (FPSIIS, FPSIRIS, FPSIRS, FASIIS, FASIRS, FASIRIS) independently predicted prognosis across all three cohorts (all plog-rank< 0.05). The CICS demonstrated an AUC of 0.690 for outcome prediction, increasing to 0.724 when combined with CEA-CA19-9. CICS-H patients exhibited reduced chemosensitivity to both agents, with therapeutic benefits primarily confined to the CICS-L subgroup. Comparable favorable RFS was observed in stage II CICS-L patients undergoing 5-FU monotherapy or oxaliplatin-based ACT versus non-ACT treatments (97.73% vs 91.02% vs 91.46%, plog-rank=0.33). Superior survival outcomes and a lower recurrence rate were observed in stage II CICS-H patients receiving 5-FU compared to those receiving oxaliplatin-based ACT. Consistent oxaliplatin benefits were observed in CICS-H and CICS-L patients compared to 5-FU-treated cases in the stage III subgroup. Optimal ACT regimens for patients with CICS-L and CICS-H differ in different stages. The CICS strategy can help patients select a more optimal ACT regimen (RR=0.47, 95% CI=0.35– 0.62, p< 0.01) and enhance therapeutic efficacy (HR=0.70, 95% CI=0.53– 0.92 for RFS; HR=0.70, 95% CI=0.47– 0.97 for OS in stage III CRC).
Conclusion: CICS-quantified cancer-derived inflammation inversely correlates with the therapeutic responsiveness to 5-FU/oxaliplatin. A CICS-guided strategy maximizes survival outcomes while precision-deescalating chemotherapy use without compromising outcomes, establishing a biomarker-driven paradigm for personalized postoperative management of CRC.
Keywords: chronic inflammatory comprehensive signature, CEA-CA19-9-CICS score, oxaliplatin, 5-fluorouracil, colorectal cancer